Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada Eyes Reducing Reliance On Pricing As Sole Reward for Innovation

A New Framework For Funding Rare Disease Treatments Is Under Consideration

Executive Summary

Up-front R&D investments from third parties in an effort to share risk and reduce industry’s reliance on pricing as the sole reward for innovation could be on the cards in Canada, as could a  new single approach for deciding which drugs to cover.

You may also be interested in...



New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

UK: Commercial Framework Sheds Light On Working With NHS And NICE

The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.

Time Is Ripe For Global Action On Orphan Biosimilars

European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel